{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:09:19Z","timestamp":1780481359895,"version":"3.54.1"},"reference-count":71,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,10,13]],"date-time":"2010-10-13T00:00:00Z","timestamp":1286928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the Philadelphia chromosome (Ph), which results in the synthesis of the breakpoint cluster region\u2010Abelson murine leukemia (BCR\u2010ABL) fusion oncoprotein, a constitutively active tyrosine kinase. The introduction of imatinib, a tyrosine kinase inhibitor (TKI) that is specific for BCR\u2010ABL, was a major breakthrough in CML therapy. Although most patients respond to first\u2010line imatinib therapy, some experience loss of response (resistance) or require treatment discontinuation because of toxicity (intolerance). For patients with CML, failure on standard\u2010dose imatinib therapy (400 mg daily), imatinib dose escalation (600\u2010800 mg daily) is a second\u2010line option. However, high\u2010dose imatinib is not an appropriate approach for patients who experience drug toxicity, and there remain questions over the durability of responses achieved with this strategy. Alternative second\u2010line options include the TKIs dasatinib and nilotinib. A substantial amount of long\u2010term data for these agents is available. Although both are potent and specific BCR\u2010ABL TKIs, dasatinib and nilotinib exhibit unique pharmacologic profiles and response patterns relative to different patient characteristics, such as disease stage and BCR\u2010ABL mutation status. To optimize therapeutic benefit, clinicians should select treatment based on each patient's historic response, adverse\u2010event tolerance, and risk factors. Cancer 2010. \u00a9 2010 American Cancer Society.<\/jats:p>","DOI":"10.1002\/cncr.25656","type":"journal-article","created":{"date-parts":[[2010,10,13]],"date-time":"2010-10-13T09:36:24Z","timestamp":1286962584000},"page":"897-906","source":"Crossref","is-referenced-by-count":56,"title":["Long\u2010term outcomes in the second\u2010line treatment of chronic myeloid leukemia"],"prefix":"10.1002","volume":"117","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,10,13]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"205","article-title":"Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia","volume":"3","author":"Ramchandren R","year":"2009","journal-title":"Biologics."},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904293401706"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct071828"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-008-0100-y"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2006.12.007"},{"key":"e_1_2_7_7_2","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell PC","year":"1960","journal-title":"Science."},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.7.973"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2004.03.012"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_2_7_13_2","first-page":"2","article-title":"New dosing schedules of dasatinib for CML and adverse event management","volume":"23","author":"Wong SF.","year":"2009","journal-title":"J Hematol Oncol."},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_2_7_15_2","unstructured":"Gleevec [package insert]. East Hanover NJ: Novartis Pharmaceuticals Corporation;2009."},{"key":"e_1_2_7_16_2","article-title":"International randomized study of interferon vs STI571 (IRIS) 8\u2010year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib [abstract]","volume":"114","author":"Deininger M","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.219"},{"key":"e_1_2_7_19_2","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. Version 2.2010. Jenkintown Pa: NCCN; 2009.http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/cml.pdf.Accessed September 24 2009."},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2007.10.001"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2896"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404318"},{"key":"e_1_2_7_24_2","first-page":"186","article-title":"International randomized study of interferon versus STI571 (IRIS) 7\u2010Year follow\u2010up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib (IM) [abstract]","volume":"112","author":"O'Brien SG","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_25_2","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1200\/jco.2007.25.18_suppl.7045","article-title":"Discontinuation and dose modification of imatinib in clinical practice [abstract]","volume":"25","author":"Hamdan MY","year":"2007","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3530"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1928"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1451"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2042"},{"key":"e_1_2_7_31_2","first-page":"2092","article-title":"The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment","volume":"9","author":"Zonder JA","year":"2003","journal-title":"Clin Cancer Res."},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24504"},{"key":"e_1_2_7_33_2","unstructured":"Sprycel [package insert]. Princeton NJ: Bristol\u2010Myers Squibb Company;2009."},{"key":"e_1_2_7_34_2","unstructured":"Tasigna 2009 Novartis Pharmaceuticals Corporation East Hanover NJ"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0170"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5015"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046888"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046839"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-073528"},{"issue":"20","key":"e_1_2_7_43_2","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1200\/jco.2008.26.15_suppl.7009","article-title":"Dasatinib 2\u2010year efficacy in patients with chronic\u2010phase chronic myelogenous leukemia (CML\u2010CP) with resistance or intolerance to imatinib (START\u2010C) [abstract]","volume":"26","author":"Mauro MJ","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_44_2","article-title":"Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML\u2010CP) [abstract]","volume":"112","author":"Baccarani M","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"issue":"1","key":"e_1_2_7_45_2","first-page":"391","article-title":"Dasatinib efficacy in patients with imatinib\u2010resistant\/\u2010intolerant chronic myeloid leukemia in accelerated phase 24\u2010month data from START\u2010A [abstract]","volume":"93","author":"Rea D","year":"2008","journal-title":"Haematologica"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"e_1_2_7_47_2","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1200\/jco.2009.27.15_suppl.7007","article-title":"Dasatinib dose\u2010optimization study in chronic phase chronic myeloid leukemia (CML\u2010CP): Three\u2010year follow\u2010up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression\u2010free survival (PFS) [abstract]","volume":"27","author":"Stone RM","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-186817"},{"key":"e_1_2_7_49_2","first-page":"3226","article-title":"Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with chronic myeloid leukemia in blast phase (CML\u2010BP): 2\u2010year data from CA180\u2010035 [abstract]","volume":"112","author":"Saglio G","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_50_2","first-page":"2926","article-title":"Dasatinib 140 mg once daily (QD) has equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with imatinib\u2010resistant or \u2010intolerant Philadelphia chromosome\u2010positive acute lymphoblastic leukemia (Ph+ ALL): 2\u2010year data from CA180\u2010035 [abstract]","volume":"112","author":"Larson RA","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_51_2","first-page":"1122","article-title":"Resistance, outcome and the development of mutations with dasatinib in patients with chronic\u2010phase chronic myeloid leukemia (CML\u2010CP) [abstract]","volume":"114","author":"Shah NP","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2790"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0371"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11064"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.110"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007"},{"issue":"2","key":"e_1_2_7_57_2","first-page":"0627","article-title":"Nilotinib in chronic myeloid leukemia patients in chronic phase (CML\u2010CP) with imatinib resistance or intolerance: 24\u2010month follow\u2010up results of a phase 2 study [abstract]","volume":"94","author":"Kantarjian H","year":"2009","journal-title":"Haematologica"},{"key":"e_1_2_7_58_2","first-page":"1129","article-title":"Update on imatinib\u2010resistant chronic myeloid leukemia patients in chronic phase (CML\u2010CP) on nilotinib therapy at 24 months: clinical response, safety, and long\u2010term outcomes [abstract]","volume":"114","author":"Kantarjian H","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"2","key":"e_1_2_7_59_2","first-page":"0631","article-title":"Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML\u2010AP) with imatinib resistance or intolerance: 24\u2010month follow\u2010up results of a phase 2 study [abstract]","volume":"94","author":"Hochhaus A","year":"2009","journal-title":"Haematologica"},{"key":"e_1_2_7_60_2","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1182\/blood.V112.11.3238.3238","article-title":"Nilotinib in chronic myeloid leukemia patients in chronic phase (CML\u2010CP) with imatinib resistance or intolerance: 2\u2010year follow\u2010up results of a phase 2 study [abstract]","volume":"112","author":"Kantarjian H","year":"2008","journal-title":"Blood"},{"key":"e_1_2_7_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035493"},{"key":"e_1_2_7_62_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902829425"},{"key":"e_1_2_7_63_2","first-page":"3225","article-title":"Dasatinib dose\u2010optimization in chronic phase chronic myeloid leukemia (CML\u2010CP): 2\u2010year data from CA180\u2010034 show equivalent long\u2010term efficacy and improved safety with 100 mg once daily dose [abstract]","volume":"112","author":"Shah NP","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_64_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056028"},{"key":"e_1_2_7_65_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080838"},{"key":"e_1_2_7_66_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-123950"},{"key":"e_1_2_7_67_2","first-page":"e51","article-title":"Presence or the emergence of a F317L BCR\u2010ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome\u2010positive leukemia","volume":"24","author":"Soverini S","year":"2006","journal-title":"Blood."},{"key":"e_1_2_7_68_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-197715"},{"key":"e_1_2_7_69_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214221"},{"key":"e_1_2_7_70_2","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1182\/blood.V114.22.3298.3298","article-title":"Prognostic factors for progression\u2010free survival in patients with imatinib\u2010resistant or \u2010intolerant chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with nilotinib based on 24 month data","volume":"113","author":"Kantarjian HM","year":"2009","journal-title":"Blood"},{"key":"e_1_2_7_71_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1516"},{"key":"e_1_2_7_72_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24257"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25656","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:20:57Z","timestamp":1760300457000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25656"}},"subtitle":["A review of tyrosine kinase inhibitors"],"short-title":[],"issued":{"date-parts":[[2010,10,13]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1002\/cncr.25656"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25656","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,13]]}}}